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ABSTRACT: Indocyanine green (ICG) is a fluorescent dye with a strong emission in the
near-infrared spectral range that allows deep signal penetration and minimal interference
of tissue autofluorescence. It has been employed in clinics for different applications, among
which the more interesting is certainly near-infrared fluorescence image-guided surgery.
This technique has found wide application in surgical oncology for lymph node mapping
or for laparoscopic surgery. Despite ICG being useful for tracking loco-regional lymph
nodes, it does not provide any information about cancer involvement of such lymph nodes
or lymphatic vessels, lacking any tumor-targeting specificity. However, the clinical need in
surgical oncology is not only a specific tracking of metastatic nodes but also the
intraoperative detection of micrometastatic deposits. Here, we have exploited a
nanotechnological solution to improve ICG usefulness by its encapsulation in H-ferritin
(HFn) nanocages. They are natural protein-based nanoparticles that exhibit some very
interesting features as delivery systems in oncological applications because they display
specific tumor homing. We show that HFn loaded with ICG exhibits specific uptake into
different cancer cell lines and is able to deliver ICG to the tumor more efficiently than the free dye in an in vivo model of TNBC. Our
results pave the way for the application of ICG-loaded HFn in fluorescence image-guided surgery of cancer.
■ INTRODUCTION
Indocyanine green (ICG) is an amphiphilic tricarbocyanine
fluorescent dye with a strong fluorescence emission in the
near-infrared (NIR) spectral range (700−900 nm). This allows
deep penetration of the signal and minimizes interference of
tissue autofluorescence.1 ICG has been used in clinics for more
than 60 years, and it is approved for different applications, such
as measuring cardiac output, ophthalmic angiography, and liver
clearance evaluation.2−4 More recently, ICG has also been
employed in NIR fluorescence image-guided surgery (FGS).5
FGS has found application mainly in surgical oncology, where
endoscopic administration of ICG has allowed successful
lymph node mapping (LNM) both for colo-rectal cancer
undergoing laparoscopic surgery and for breast cancer.6−8
More than 150 clinical trials are now being conducted using
ICG for FGS in several types of cancer, including breast,
gastric, colon, prostate, skin, and lung cancers, and promising
results have already been reported.9
Despite feasibility and accuracy of ICG being demonstrated
for real-time LNM and tracking of loco-regional lymph nodes,
ICG does not provide any information about cancer
involvement of such lymph nodes or lymphatic vessels, lacking
any specific targeting toward tumor cells.10 Furthermore,
clinical applications of ICG currently rely on knowledge about
primary tumor localization because a subdermal or submucosal
injection is required for LNM.11 However, surgeons would
need not only a specific tracking of metastatic nodes but also to
detect intraoperatively micrometastatic deposits (i.e., tumor
deposits not associated to lymph nodes in rectal cancer or
microscopic peritoneal carcinomatosis in gastric or ovaric
cancer).12
Therefore, in the attempt of developing an in vivo
fluorescent tracer able to specifically label tumor tissue, the
exploitation of a tumor-targeted ICG-based nano-delivery
system could represent an interesting tool. Several nano-
technological approaches have been proposed for ICG
delivery, mainly using micelles,13 polymeric nanoparticles,14−17
silica nanoparticles, and liposomes,18−20 but their tumor
specific accumulation has been hardly demonstrated. Indeed,
in these ICG-based nanoparticles, dye accumulation into the
target site is mainly triggered by the enhanced permeation
effect (EPR). Therefore, ICG accumulates also into tissues
surrounding the tumor mass, thus preventing the correct
discrimination between non-cancerous and cancerous tissues.21
Despite this, these strategies have allowed to improve ICG
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fluorescence stability and increasing circulation time, solving
some issues that actually prevent free ICG intravenous
administration, such as the quick loss of fluorescence in
aqueous media and the strong quenching effect observed at
higher dye concentrations.21 Here, we try to combine the
advantages related to ICG nanoformulation with tumor target
specificity thanks to the exploitation of H-ferritin (HFn)
nanocages loaded with the dye for intraoperative detection of
tumor.21−23
HFn is a protein nanocage that displays a cave sphere
structure of 12 nm in diameter constituted by 24 self-
assembling subunits.24,25 From the nanotechnological point of
view, HFn exhibits some very interesting features combining a
low toxicity because of its protein nature with a particularly
high tumor homing ability.26,27 Indeed, HFn binding and
internalization in cells is mediated by the transferrin receptor-1
(TfR1), which is highly overexpressed in cancers.28 Moreover,
HFn is highly stable in biological fluids and extremely resistant
to high temperatures (up to 80 °C) and to acidic conditions: at
low pH, HFn subunits are disassembled, with the possibility of
loading different cargoes inside the cavity, while they are
naturally reassembled when pH is brought back to neutral.29
These characteristics make HFn a very promising nanocarrier
in oncological applications. Several HFn-based nanodrugs have
been developed for cancer treatment at a preclinical level with
excellent results in terms of specific tumor recognition,
improved drug penetration, optimized subcellular targeting,
increased activity with lower side effects, and reduced onset of
chemoresistance.30−33
In this work, we prepared ICG loaded HFn nanocages
(HFn−ICG) and we assessed their uptake into different
gastric, breast, and colo-rectal cancer cell (CC) lines.
Moreover, we evaluated HFn−ICG biodistribution in a
preclinical model of breast cancer demonstrating that ICG
can be specifically internalized into tumor cells and delivered
to the tumor mass thanks to the strong targeting affinity of
HFn with TfR1. Our results prove the suitability of HFn−ICG
as an in vivo nanotracer for FGS and intraoperative detection of
tumors.
■ RESULTS AND DISCUSSION
HFn Suitability as an ICG Delivery Vector. In the
attempt of supporting surgeons in intraoperative tumor and
metastasis localization, the exploitation of a nanoparticle-based
ICG delivery system able to specifically label cancer tissues
would have a relevant translational impact. Among the plethora
of possibilities offered by nanotechnology, we have reasoned
that HFn nanocages could represent the most valuable
solution. Indeed, these nanoparticles displayed (1) a cave
sphere structure loadable with dyes, (2) good biocompatibility
and solubility profile due to its protein nature, and (3) a
natural tumor homing.
In addition to this, we have also hypothesized that tumor-
targeted ICG nanoparticles could be applied in FGS of certain
kinds of tumors, such as breast, colo-rectal, and gastric cancers.
Therefore, we have established a panel of human CC lines,
selecting MCF-7, HCC1937, MDA-MB 231, and MDA-MB
468 among breast CC lines, while SNU-16, HT-29, and
HCT116 as models of gastric and colo-rectal cancer,
respectively. Because HFn interaction and internalization in
CCs is mediated by its capability to specifically recognize the
TfR1 overexpressed in a lot of cancers,28 we have first
evaluated TfR1 expression in the surface of these cell lines by
flow cytometry.
Surface expression of TfR1 reported in Figure 1a,b
evidenced that CC lines included in our panel could be
distinguished into two groups: one that displays high TfR1
expression and one characterized by a lower TfR1 expression:
HT-29, HCT116, MCF-7, and SNU-16 exhibited 3−5 fold
higher TfR1 expression than HCC1937, MDA-MB 231, and
MDA-MB 468. To better define TfR1 overexpression in the
CC lines used in the present study, we compared our results
with data we previously published, in which the low TfR1
expressing CCs used here displayed a TfR1 expression higher
than the one observed in a healthy control cell line, such as
human umbilical vein endothelial cells, which among healthy
cells is characterized by a relatively high TfR1 expression.31
Figure 1. HFn specific interaction with CC lines. TfR1 expression of
CC lines tested by cytofluorimetry expressed as mean fluorescence
intensity (a) and as percentage of positive cells (b). Cells
immunodecorated with the anti-mouse secondary antibody con-
jugated with Alexa Fluor 488 were used to set the gate on viable cells,
on singlets, and the region of positivity. (c) HFn−F binding with
CCs. Cells were incubated 2 h at 4 °C in PBS buffer and 0.3% BSA
with different amounts of HFn−F (20 and 100 μg/mL). Cells were
processed for flow cytometry using untreated cells to set the positive
region and the singlet gate. (d) Competition assay in HT-29 cells
(high TfR1 expression) incubated with 500 μL of HFn−F (20 μg/
mL) at 4 °C for 2 h with or without an excess of unlabeled HFn (1
mg/mL) as competitor. Cells were then detached and treated for flow
cytometry. Untreated cells have been used to set the singlet gate and
the positive region. Data are reported as average ± S.D. of three
independent experiments and expressed as panel (a), mean
fluorescence intensity (M.F.I., ×105); panel (b), percentage of cells
in the positive region to HFn−F fluorescence and; panel (c), relative
fluorescence intensity (R.F.I., %).
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Moreover, we evaluated TfR1 expression in another cell line
of normal mammary tissue, (MCF-10A) where we obtained
0.2% of TfR1+ cells (data not shown). This is much lower than
all other CCs tested here that were all between 12% (MDA-
MB 231) and 98% (HCT116) (Figure 1b).
Then, we have evaluated the binding of fluorescently labeled
HFn nanocages with our panel of CCs (Figure 1c). FITC was
covalently conjugated to HFn (HFn−F) by amide-bond
formation between Lys residues on HFn and the carboxyl
group on FITC to avoid issues related to dye leakage during
incubation with cells and to analyze only cells that were
actually bound to HFn excluding those simply stained by the
free dye. CCs were incubated for 2 h at 4 °C with two different
amounts of HFn−F (20 and 100 μg/mL) and then analyzed by
flow cytometry. Interestingly, we found that the panel of CCs
could be easily divided into the same two groups observed
when studying their TfR1 expression. CCs with high
expression of TfR1 (HT-29, HCT116, MCF7, and SNU-16)
displayed high percentages of binding already at the lowest
HFn−F concentration (i.e., 20 μg/mL). Here, 80−90% of cells
were positive to HFn−F staining at the low dose, while these
percentages reached 100% at the higher dose of 100 μg/mL.
On the contrary, HCC1937, MDA-MB 231, and MDA-MB
468, which exhibited lower TfR1 expression, showed much
lower interaction with HFn−F. Once again, we could observe a
dose-dependent recognition, as demonstrated by the increase
in binding percentages when incubating cells with 100 μg/mL
of HFn−F. Binding assay performed with a cell line of normal
mammary tissues (i.e., MCF10A) reported in Figure S1
suggests the suitability of HFn as the tumor-targeted delivery
system.
To further characterize HFn−F cell interaction and to verify
if this is actually mediated by TfR1 expression, we ran a
competition binding assay using HT-29 cell line. Keeping cells
at 4 °C to avoid endocytosis, we first incubated cells with a 50
fold excess of unlabeled HFn [1 mg/mL in phosphate buffered
solution (PBS)], as a competitor. Then, we added HFn−F at a
concentration of 20 μg/mL and evaluated the binding
efficiency. As it is shown in Figure 1d, we observed a strong
competition with a 60% binding reduction, which confirms the
specificity of the interaction between CC and HFn nanocages.
One more time, the crucial role of TfR1 in mediating CCs−
HFn interaction has been stated, demonstrating HFn
suitability as an ICG delivery vector.
HFn Efficiently Encapsulates ICG and Stabilizes Its
Fluorescence Properties. To perform HFn loading with
ICG, we have followed the procedure illustrated in Figure 2a
and widely used in literature to load drugs and other dyes into
ferritin nanocages.34,35 Briefly, HFn was unfolded lowering the
pH to 2.0, and then, the protein was refolded bringing back the
pH to neutrality. ICG was added at the beginning of the HFn
refolding process and incubated at room temperature (RT) for
about 2 h. Non-encapsulated ICG has been removed by size
exclusion chromatography, loading the formulation in Zeba
spin desalting columns.
Encapsulation of ICG was confirmed by Raman spectros-
copy. In Figure 2b, the spectra of ICG in solution after
encapsulation in HFn nanocages are reported. As it can be seen
in the figure, typical peaks of free ICG (lower panel) were also
detected in the spectrum of HFn−ICG (higher panel), thus
confirming the effective loading of the dye into HFn
nanocages.
To verify the integrity of HFn after ICG loading, we have
analyzed their structure by transmission electron microscopy
(TEM) (Figure 2c). The images clearly evidenced both the
inner cavity of the nanocages and the circular outer shape and
confirmed HFn−ICG structural integrity, with the single
subunits of the protein that can be observed in the zoomed
Figure 2. Development and characterization of ICG-loaded HFn nanocages. (a) Schematic representation of the pH-dependent disassembly/
reassembly method used for HFn loading with ICG. ICG is represented in green and HFn is represented in gray. (b) Raman characterization of
HFn−ICG nanoformulation; the peaks of free ICG (green highlights) are also found in HFn−ICG samples, meaning that the dye was efficiently
loaded within the nanoformulation. (c) TEM images of HFn−ICG at different magnifications and (d) a representative profile plot confirming the
size of the nanoassembly, with an inner and outer shells of approximately 8 and 12 nm, respectively.
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images of the lower-left corner of the panel. We then analyzed
the profile plot of the nanocages to confirm the final size of the
structure (Figure 2d). As expected, we obtained nanocages
with an inner size of 8 nm and an outer diameter of 12 nm,
thus confirming the size of HFn reported in literature.36
A quantitative analysis of ICG loading efficiency was
performed by spectrofluorimetry. First, we have measured
the fluorescence of the nanocomposites and compared it with a
standard curve of the dye. To obtain a reliable standard curve,
we have evaluated ICG fluorescence in different media, as it is
known that its emission properties radically change depending
on the medium where the dye is dissolved.37 As it can be seen
in Figure S2, the fluorescence yield in water and PBS is much
lower than in media containing lipids and proteins, such as
Dulbecco’s modified Eagle medium (DMEM), plasma, and
milk. Moreover, a linear correlation between ICG fluorescence
and dye concentration could be obtained only working in
complex media (i.e., DMEM, plasma, and milk). Milk was
particularly reliable in terms of measurement reproducibility
and sensitivity, so we have decided to use it to perform the
quantification of ICG encapsulation. We have prepared a
standard curve by diluting different concentrations of ICG in
milk (Figure S3, panel a), and we have observed a maximum
value of fluorescence emission at around 10−20 μM ICG
solution. Above this concentration, the peak shifted from 805−
810 to 820 nm, and the fluorescence intensity started to
decrease because of a strong quenching effect, as also reported
in literature.23 To quantify the concentration of the dye inside
the HFn−ICG preparation, we have extracted ICG from the
nanocages with an acetonitrile−ddH2O solution (I), diluted in
milk (II), and we have compared the fluorescence values with
the standard curve (III). We have tested different dilutions to
avoid quenching effect. The average concentration of loaded
dye was 1.01 ± 0.07 mg/mL, corresponding to a loading
efficiency of 40.4 ± 4.5% of the initial dye that was reacted
with HFn. The effectiveness of ICG encapsulation is strongly
Figure 3. Stabilization of ICG upon nanoformulation. (a) Evaluation of the fluorescence lifetime of HFn−ICG (continuous line) and free ICG
(dashed line) in ddH2O by spectrofluorimetry. (b) ICG release from HFn−ICG evaluated by spectrofluorimetry after 14 days dialysis in ddH2O at
4 °C.
Figure 4. HFn−ICG interaction with TfR1high CCs. (a−d) Representative flow cytometry plots showing cell binding with 20, 50, and 100 μg/mL
of HFn−ICG (light green, purple, and blue curves, respectively, black curves = control cells) after 2 h incubation at 4 °C. (e−h) Representative
confocal microscopy images of cells incubated with HFn−ICG for 2 h at 4 °C to evaluate binding and TfR1 colocalization (blue = cell nuclei
stained with DAPI, cyan = cell membrane, green = HFn−ICG, and purple = αTfR1 antibody staining). (i−l) Cellular uptake of HFn−ICG NPs
evaluated by IVIS analysis, after incubation at 37 °C for different time points. High TfR1 expression lead to high binding, diffused colocalization
with TfR1 (white spots) and strong HFn−ICG uptake.
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supported also by some indirect data. As shown in Figure S3
(panel b), after acetonitrile extraction of the dye, the
fluorescence intensity of ICG increased and the maximum
peak shifted from 820 to 810 nm. This suggests that the dye
was entrapped inside HFn and its fluorescence quenched.
Moreover, the average size observed for HFn−ICG nanocages
did not vary as compared to empty HFn, proving that the dye
is encapsulated inside HFn cavity and not simply adsorbed on
the protein shell. These data coupled with Raman spectra
demonstrating the presence of ICG in the final product
strongly prove that the dye has been efficiently encapsulated
inside the nanocages.
After verifying that the dye had been encapsulated in the
nanocages, we have tested whether the protein shell would
stabilize its fluorescence properties. In fact, ICG low
fluorescence stability is a big issue with the use of ICG in
clinical practice.22 To verify this, we have measured the
fluorescence decay of both HFn−ICG and ICG until we
reached the limit of detectability for the free dye (about 800
min) (Figure 3, panel a). At this time point, the fluorescence of
the encapsulated ICG was still 40% of the initial value with a
much slower decay rate (−0.392 fluorescence units/minute for
HFn−ICG as compared to −0.590 fluorescence units/minute
for free ICG). The two curves are significantly different
because the free ICG displayed a regular decay profile, while
the nanoformulated one is more irregular, suggesting that only
the fraction of dye released over time is degraded, while the
dye that is still encapsulated inside the protein cavity is
protected from degradation, thus improving ICG fluorescence
lifetime. These data confirm the role of HFn encapsulation in
stabilizing ICG fluorescence.
To further characterize HFn−ICG, we have analyzed the
kinetics of ICG release from HFn nanocages by dialysis. As it
can be seen in Figure 3b, the profile is very regular, with no
evident burst effect during the first hours of incubation, and
around 50% of the dye is released from HFn during the first 72
h, suggesting a good stability of the complex. After this time
point, the release slows down, reaching a plateau after 1 week
of incubation, when 66% of the dye has been released. We
continued the analysis for one more week, but no further
increase in fluorescence was recorded, meaning that no more
ICG has been released in solution. Representative pictures of
the samples collected throughout the dialysis are shown in
Figure S4. Interestingly, HFn−ICG collected from inside the
dialysis membrane (t14in) are still of a bright green, almost as
intense as the one at the beginning of analysis (t0in), thus
confirming the high stability of the complex.
Dose-Dependent HFn−ICG Binding with CCs. To
further characterize the interaction of HFn−ICG with our
panel of CCs, we performed a binding assay with increasing
concentrations of loaded nanocages (Figures 4a−d and 5a−c).
Similar experiments with free ICG have not been performed
because ICG undergoes non-specific binding and internal-
ization. We incubated cells with three different HFn−ICG
concentrations (20, 50, and 100 μg/mL), and we studied by
flow cytometry the fluorescence distribution associated with
cell interactions. Results demonstrated that the binding with
cells is dose-dependent in all cell lines, as the mean
Figure 5. HFn−ICG interaction with TfR1low CCs. (a−c) Representative flow cytometry plots showing cell binding with 20, 50, and 100 μg/mL of
HFn−ICG (light green, purple, and blue curves, respectively, black curves = control cells) after 2 h incubation at 4 °C. (d−f) Representative
confocal microscopy images of cells incubated with HFn−ICG for 2 h at 4 °C to evaluate binding and TfR1 colocalization (blue = cell nuclei
stained with DAPI, cyan = cell membranes, green = HFn−ICG, and purple = αTfR1 antibody staining). (g−i) Cellular uptake of HFn−ICG
evaluated by IVIS analysis, after incubation at 37 °C for different time points. Low TfR1 expressions lead to low binding, low uptake, and low
colocalization with TfR1.
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fluorescence intensity increases up to the concentration of 100
μg/mL. As expected, in CCs with high TfR1 expression, we
reached 100% of stained cells already at the lowest
concentration of ICG (i.e., HFn−ICG at 10 μg/mL) (Figure
4a−d), despite the mean fluorescence intensity still increasing
in a dose-dependent manner, suggesting that the binding is not
saturated yet. Even more interestingly, we observed a dose-
dependent increase in binding, also in cells with low TfR1
expression (Figure 5a−c). This, together with the low but
specific binding observed with HFn−F (Figure 1b) suggests
that even a low TfR1 expression is enough to obtain a specific
ICG label of CCs, evidencing the suitability of HFn as a
nanodelivery system for ICG.
TfR1 is Involved in HFn−ICG Uptake in CCs.
Involvement of TfR1 in mediating binding and uptake of
HFn−ICG nanocages has been assessed by confocal
microscopy. CCs were incubated with HFn−ICG for 2 h at
4 °C and stained with an anti-TfR1 antibody. Representative
images of CCs with high levels of TfR1 are reported in Figure
4e−h, where the strong purple signal, observed in almost all
analyzed cells, confirmed the high expression of the receptor.
Here, the HFn−ICG signal (green) is mostly associated with
cell membranes and partially diffused in peripheral areas of the
cytoplasm. Moreover, the majority of the HFn−ICG signal
seems to colocalize with TfR1 staining with a dotted-
distribution that reminds association with TfR1 rich endo-
somes that are involved in iron metabolism.38 The
colocalization around cell membranes was somehow expected.
Even if incubation was performed at 4 °C, a portion of
nanocages seem to be distributed intracellularly. This might be
due to the strong interaction with TfR1 and the fast uptake
kinetics that are characteristics of this receptor.39
In Figure 5d−f, HFn−ICG interaction with low TfR1
expressing CCs (HCC1937, MDA-MB 231, and MDA-MB
468) has been depicted. In these CCs, not all cells were TfR1+,
confirming that the low expression obtained by flow cytometry
(Figure 1b). Quite interestingly, HFn−ICG signal was almost
exclusively found around TfR1+ cells, where strong accumu-
lation on cell membranes and very rare colocalization spots
were observed inside the cells. On the contrary, almost no
HFn−ICG interaction was observed with TfR1− cells.
Further indirect confirmation of the TfR1 involvement in
CCs uptake of HFn−ICG was obtained by studying the
intracellular accumulation of ICG by IVIS Lumina II, for
different time points (Figures 4i−l and 5g−i). To avoid
fluorescence quenching problems normally observed at high
ICG concentrations, we extracted the dye with a 1:1 solution
of acetonitrile and water. This allowed us to release the dye
from intracellular vesicles, where it could reach a relatively high
local concentration into the acetonitrile-based solution and
maximize its fluorescence emission. In all CCs, we obtained a
time-dependent intracellular uptake of HFn−ICG, where the
Figure 6. Colocalization of HFn−ICG and TfR1. (a,b) Confocal images of MDA-MB 231 cells incubated 15 min, 1, 3, 24, and 48 h at 37 °C in
complete cell culture medium with HFn−ICG or free ICG [green; 50 μg/mL; panel (a,b), respectively]. Nuclei were stained with DAPI (blue).
TfR1 was recognized with anti-TfR1 antibody (Abcam) and labeled with an anti-rabbit secondary antibody conjugated with Alexa Fluor 488. Scale
bar = 50 μm.
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fluorescent signal was detectable already after 15 min of
incubation. The signal slightly increased over time, with
minimal differences up to 6 h, while it reached the highest
intensity after 48 and 72 h of incubation. As expected, we have
noticed that TfR1 high expression led to a 2−5 times higher
particle uptake than in low TfR1 expressing cells. The
maximum signal has been reported in HCT116 and HT-29,
while the lowest fluorescence has been revealed in HCC1937
cells.
Nanoformulation Affects ICG Uptake and Accumu-
lation. We further studied intracellular uptake of ICG by
incubating MDA-MB 231 cells with both free and nano-
formulated ICG and observing the distribution of the
fluorescence signal over time by confocal microscopy.
Among all the tested CCs, we selected MDA-MB 231 to
prove that HFn encapsulation could significantly improve
intracellular uptake of ICG even in cells, where TfR1 is not at
its maximum expression. The fluorescence signal of HFn−ICG
(green) gradually increased (Figure 6a): it remained very low
within the first hour of incubation, while it started to be clearly
visible after the third hour of incubation. The dotted
distribution of intracellular HFn−ICG seems to confirm a
vesicle-mediated uptake mechanism, with subsequent peri-
nuclear accumulation, as expected for a transferrin mediated
uptake, which is characterized by binding with TfR1 on the cell
membrane, clathrin-mediated endocytosis, accumulation into
late endosomes, and then recycling to the cell membranes.40
On the contrary, the uptake pattern observed for free ICG was
completely different (Figure 6b). The signal was already visible
inside the cells after 15 min of incubation and, opposite to
HFn−ICG, it did not seem to increase over time. This might
be due to the low uptake of the free dye in the cells and to a
fast degradation of the molecule with consequent fluorescence
loss. As expected, no perinuclear ICG accumulation and no co-
localization with TfR1 were observed for ICG, suggesting that
the dye does not follow the same pathway of HFn−ICG.
To corroborate these observations, we have decided to
perform also a pilot experiment in vivo with the aim to
demonstrate the improved uptake performances of nano-
formulated ICG in comparison to ICG free. To reach this goal,
we have used an in vivo ortotopic and syngeneic model of
murine breast cancer, obtained by injection of 4T1 cells into
the mammary fat pad of Balb/C female mice. This model has
been selected because 4T1 cells display low TfR1 expression41
and low binding with HFn nanocages as previously
demonstrated.30 Therefore, obtaining good targeting results
with this model could reasonably allow us to hypotesize that
better results could be obtained with tumors characterized by
higher expression of TfR1 and better HFn recognition. Indeed,
a different but non-significant trend in tumor accumulation of
ICG has been detected after administration in mice treated
with the free dye or with HFn−ICG, as reported in Figure 7
(p-value = 0.1112). By in vivo fluorescence imaging performed
6 h after administration, we observed a strong HFn−ICG
signal localized in the tumor mass, while free ICG did not
display specific intratumor accumulation. The free dye was
only detected in the liver and the intestine tract. This was
expected as it is widely known that free ICG is rapidly
metabolized in the liver and released in the intestine together
with bile salts to be excreted in the stool.42 The fluorescent
signal observed in the lower abdominal area in HFn−ICG-
treated mice is most likely due to both the non-tumor
accumulated HFn nanocarrier that is being metabolized and to
free dye that has been partially released from HFn in the
meantime.
Figure 7. In vivo tumor targeting of HFn−ICG and ICG. In vivo targeting of HFn−ICG (a,c) and ICG (b,d) was evaluated in tumor-bearing mice,
6 h after I.V. administration by IVIS Lumina II and by KARL STORZ NIR/ICG endoscopic system. (e) Imaging analysis of data obtained by IVIS
Lumina II allowed us to quantify the dye in the tumor area (black dotted ROI). Fluorescence was higher in HFn−ICG than in free ICG-treated
mice, but the difference was not statistically significant (p-value = 0.1112). Color scale expressed as total radiant efficiency (×108), n = 3.
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Twenty four hours after administration, no fluorescence was
observed either in HFn−ICG- or free-ICG treated mice, with
no undesirable accumulation of either the carrier and the dye
(Figure S6).
Overall, the improved fluorescence properties, the high
cellular uptake efficacy, and the ability of targeting the tumor
mass in vivo suggest the great potential of HFn−ICG as an
exploitable delivery agent for ICG in solid tumors.
■ CONCLUSIONS
ICG is routinely used in surgical oncology for LNM mapping
and FGS with good results. However, ICG labels cancer in a
not specific way, limiting the FGS application in tumor with
well-known localization. Here, tumor specific delivery of ICG
was successfully achieved in a wide panel of CC lines using
HFn as the tumor targeted delivery system for ICG, allowing
its use to detect, label, and potentially remove also unknown
micrometastatic tumor deposits. Indeed, HFn is naturally
internalized by CCs thanks to TfR1-mediated endocytosis and
displays an inner cavity easily loadable with hydrophilic drugs
or contrast agents. Therefore, ICG can be loaded into HFn
with a loading efficiency of more than 40%, and it can be
delivered into a wide panel of CCs depending on their TfR1
expression, allowing achievement of tumor targeting capability
to ICG. Moreover, nanoformulation in HFn nanocages
improves the fluorescence properties of ICG and avoids its
quick degradation, increasing retention time in the body.
These promising results confirm the ability of HFn to deliver
ICG specifically to the tumors and pave the way for the
application of HFn−ICG in FGS of cancer.
■ MATERIALS AND METHODS
Development of ICG-Loaded-HFn Nanoparticles. HFn
was purchased from MoLiRom s.r.l. (Rome, Italy). For in vitro
preliminary studies with the panel of CCs, HFn was labeled
with fluorescein isothiocyanate Isomer I (Sigma-Aldrich S.r.l.,
CAS Number: 3326-32-7, Milan, Italy) according to the
manufacturer’s protocol. ICG has been nanoformulated
exploiting the ability of HFn to disassemble and reassemble
its quaternary structure in response to changes in pH. First, a
mixture of HFn (0.5 mg/mL) dissolved in 0.15 M NaCl was
brought to pH 2.0 for 15 min at RT to disassemble the protein
cage. Then, the pH was brought back to neutrality. In the
meantime, ICG powder Verdye (25 mg; Diagnostic Green
GmbH, Aschheim-Dornach, Germany) was solubilized in
bidistilled deionized water (5 mL; 5 mg/mL) and immediately
added to the HFn solution at a final dye concentration of 1
mg/mL. The mixture was incubated for 2 h at RT to allow
complete refolding of the HFn quaternary structure. The
resulting HFn−ICG nanoparticles were then concentrated by
means of Amicon Ultra-4 centrifugal filter devices (Merck
S.p.a., Milan, Italy, Catalog Number: UFC810024). Unloaded
ICG has been removed by gel filtration using a Zeba Spin
Desalting column (Thermo Fisher Scientific, Monza, Italy;
Catalog Number: 89890).
Transmission Electron Microscopy. A drop of HFn
suspension was dried on the Formvar net at RT, stained with
uranil-acetate 1% for 30 s at RT and dried over night at RT.
Samples were evaluated by TEM (Tecnai Spirit, FEI).
Magnification 300,000× and 80,000×. High-magnifications
images were further elaborated with the Profile Plot ImageJ
software tool, to measure the size of HFn−ICG nanocages.
Raman Spectroscopy. Raman spectra were recorded
using an inVia Raman microscope from Renishaw (UK)
equipped with laser light sources operating at 785 nm. The
Raman spectrometer was calibrated daily using the band of
monocrystalline silicon at 520.7 cm−1. Raman spectra were
acquired from 12 μL drops of water solution of free ICG and
of HFn−ICG dried on top of a CaF2 slide (Crystran, UK)
without any further preparation. Spectra were collected using a
785 nm laser line of 6.25 mW focused on the sample using a
100× objective for 10 s. Shown spectra are the averaging of six
acquisitions after baseline subtraction and vector normal-
ization.
Analysis of ICG Fluorescence Properties and Quanti-
fication of ICG Encapsulation Efficiency. The fluorescence
properties of free and encapsulated ICG were studied in
different media by fluorescence spectroscopy (FP8300
spectrofluorometer equipped with a FMP-825 multiwell
reader; Jasco, Cremella, LC, Italy). Fluorescence yield and
emission spectrum of the dye were studied in ddH2O, PBS,
DMEM, human plasma, and milk. This analysis was mandatory
to select a solvent suitable for further quantitative analysis of
ICG encapsulation in HFN nanocages. We selected milk for its
high fluorescence yield and data reproducibility.
A standard curve was obtained by fluorescence analysis of
different concentrations of free ICG in milk at different
concentrations (1.7, 10, 20, 40, 80, and 160 μM) and was used
to quantify the amount of ICG loaded inside the HFn
nanocages. To avoid issues due to differences in fluorescence
properties between free and encapsulated ICG, the dye was
first extracted from the nanocages and then quantified. To this
aim, 80 μL of cold acetonitrile was added to 20 μL of the
HFn−ICG sample. The mixture was vortexed and centrifuged
at 14,000 rpm for 10 min in order to precipitate denatured
HFn and release encapsulated ICG in solution. Then, different
dilutions were prepared to avoid quenching effect, and
fluorescence emission of the extract was measured with an
excitation wavelength of 730 nm. Results were interpolated
with the standard curve to calculate the amount of
encapsulated ICG. Experiments were performed in triplicate.
Kinetics of Spontaneous ICG Release In Vitro. HFn−
ICG was loaded in a dialysis device (Float-A-lyzer G2 Dialysis
Device MWCO: 100 KD, Spectrum Labs, Compton, CA,
USA) and kept in a water bath at 4 °C for 14 days. At
predetermined time points (15 min, 1, 2, 3, 18, 24, 48, 72, 96
h, 6, 7, 8, and 14 days), 5 mL of buffer was collected, replaced
with fresh buffer in order to maintain the sink condition, and
the fluorescence of each collected sample was measured by
spectrofluorimetry. Moreover, the decay in fluorescence of
HFn−ICG was studied in parallel for the whole duration of the
dialysis. To calculate the relative amount of released ICG at
each time point, the fluorescence value was interpolated with
the calibration curve, as already described, and normalized with
the fluorescence decay measured throughout the dialysis
period (data not shown). This allowed us to obtain 100%
recovery of the initially loaded ICG. Fluorescence was
measured (λexc: = 760 nm, λemis: = 780 nm). All studies were
performed in triplicate.
Cell Culture. HT-29, HCT116, SNU-16, MCF7, MDA-MB
468, MDA-MB 231, HCC1937, and MCF-10A cell lines were
purchased by ATCC-LGC Standards. HT-29, HCT116, SNU-
16, and HCC1937 cells were cultured in RPMI 1640 Medium.
MDA-MB 468 and MCF7 cells in high glucose DMEM. MDA-
MB 231 cells were cultured in minimum essential medium. All
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media were supplemented with 10% heat inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U mL−1
penicillin, and 0.1 mg/mL streptomycin, except for HT-29
and HCT116 cells that were cultured in medium supple-
mented with 10% heat inactivated FBS, 1.5 mM L-glutamine,
100 U mL−1 penicillin, and 0.1 mg/mL streptomycin. MCF-
10A was cultured in MEBM medium supplemented with
MEGM kit from Lonza (CC-3150). All cell lines grew at 37 °C
in a humidified atmosphere containing 5% CO2 and were
subcultured prior to confluence using trypsin/EDTA. Cell
culture medium and chemicals for cell culture were purchased
from Euroclone.
TfR1 Expression. HT-29, HCT116, SNU-16, MCF7,
MDA-MB 468, MDA-MB 231, and HCC1937 cells (5 ×
105) were labeled with anti-TfR1 antibody diluted 1:100 [1
μg/tube; CD71 antibody (clone ICO-92), Thermo Fisher
Scientific, Catalog Number #: MA1-7657] in blocking buffer
(PBS, 2%) bovine serum albumin [BSA; Sigma-Aldrich S.r.l.,
Milan, Italy, and 2% goat serum (Euroclone S.p.A., Pero,
Italy)] for 15 min at RT and cells were washed three times
with PBS. Then, cells were labeled with Alexa Fluor 488 goat
anti-mouse secondary antibody diluted 1:200 (1 μL/tube;
Thermo Fisher Scientific, Monza, Italy; Catalog Number #: A-
11001) in blocking buffer for 15 min at RT and were washed
thrice with PBS before analysis using CytoFLEX flow
cytometer (Beckman Coulter, Cassina De’ Pecchi, Italy), and
20,000 events were acquired, after gating on viable cells and on
singlets. Cells immunodecorated only with the secondary
antibody were used to set the region of positivity.
In Tube-Cell Binding Assay at 4 °C. Cells (5 × 105) were
collected and incubated for 2 h at 4 °C in blocking buffer
(PBS, 0.3% BSA) supplemented with 20, 50, and 100 μg/mL
of FITC-labeled HFn. After incubation, cells were washed
three times with PBS, suspended in 0.5 mL of PBS, and
analyzed using a CytoFLEX flow cytometer (Beckman Coulter,
Cassina De’ Pecchi, Italy). 20,000 events were acquired for
each analysis, after gating on viable cells and on singlets. A
sample of untreated cells was used to set the appropriate gates.
Competition Assay. HT-29 cells (5 × 105) were collected
and preincubated for 2 h at 4 °C in 500 μL of 0.3% BSA−PBS
with or without 1 mg/mL of free unlabeled HFn as competitor.
Then, 20 μg/mL of FITC-labeled HFn was added for 1 h at 4
°C. Cells were washed three times with PBS and analyzed by
CytoFLEX. After gating on viable and single cells, 20,000
events were acquired for each analysis. Untreated cells were
used to set the positivity region.
Confocal Laser Scanning Microscopy. Cells (2 × 105)
were cultured until subconfluence on cover glass slides
precoated with collagen and incubated with HFn−ICG at a
concentration of for 2 h at 4 °C. After incubation, cells were
washed three times with PBS, fixed for 5 min with 4%
paraformaldehyde (Sigma-Aldrich), and washed thrice with
PBS. A blocking step was executed for 1 h at RT with a
solution containing 2% BSA (Sigma-Aldrich) and 2% goat
serum (Euroclone) in PBS. Membranes were labeled
incubating coverslips with Alexa Fluor 488 wheat germ
agglutinin (Life Technologies) diluted 1:200 in PBS for 10
min. TfR1 colocalization was revealed with the anti-TfR1
antibody (1:200; ab84036; Abcam) and recognized by Alexa
Fluor 488-conjugated antibody against rabbit IgGs (Thermo
Fischer Scientific) at a 1:300 dilution by incubating for 2 h at
RT in PBS, 2% BSA, 2% goat serum, and 0.2 μg/mL DAPI
(4′,6-diamino-2-phenylindole; Thermo Fischer Scientific).
Coverslips were mounted in Prolong Gold antifade reagent
(Thermo Fisher Scientific). Microscopy analysis was per-
formed with the Leica SP8 system equipped with laser
excitation lines at 405, 488, 552, and 633 nm, using a 63×
magnification oil immersion lens.
To evaluate kinetics of internalization of HFn−ICG and free
ICG, MDA-MB 231 cells were cultured until subconfluence on
cover glass slides precoated with collagen and incubated for 15
min, 1, 3, 24, and 48 h at 37 °C in complete cell culture
medium supplemented with HFn−ICG nanoparticles or ICG
free (green; 50 μg/mL). After incubation at the indicated time
points, cells were washed with PBS, fixed for 5 min with 4%
paraformaldehyde (Sigma-Aldrich), and then treated for 5 min
with 0.1% Triton X-100 (Sigma-Aldrich). Subsequently, a
blocking step was performed for 1 h at RT with a solution
containing 2% BSA (Sigma-Aldrich), 2% goat serum (Euro-
clone), and 0.2 μg/mL DAPI (Thermo Fischer Scientific) in
PBS. TfR1 staining was performed with the anti-TfR1 antibody
(1:200; ab84036; Abcam) recognized by Alexa Fluor 488-
conjugated antibody against rabbit IgGs (Thermo Fischer
Scientific) at a 1:300 dilution by incubating for 2 h at RT in
PBS, 2% BSA, and 2% goat serum. Coverslips were mounted in
Prolong Gold antifade reagent (Thermo Fisher Scientific), and
images were acquired with a Leica SP8 microscope confocal
system equipped with laser excitation lines 405, 488, 535, and
633 nm. Images were acquired with 63× magnification oil
immersion lens.
Cellular Uptake. Cells (1 × 103) were seeded in a black
96-well plate in order to inhibit influence of background
fluorescence during analysis. The day after seeding, cells were
treated with 50 μg/mL of HFn−ICG for different time periods
(15 min, 1, 2, 3, 4, 6, 24, 48, and 72 h) at 37 °C. After
incubation, cells were washed five times with PBS and then
100 μL of cold acetonitrile were added to each well for 24 h at
−20 °C in order to lyse cells and extract ICG. After cell lysis, a
dilution 1:2 in milk of each well suspension was made. Plate
fluorescence has been measured using the IVIS Lumina II
imaging system (PerkinElmer, Waltham, MA, USA). The
following acquisition parameters were used: excitation filter
745 nm, emission filter ICG, exposure time = 30 s, field of view
= 12.5 × 12.5 cm, binning factor = 2, and f/stop = 2. Image
processing and analysis were done using Living Image 4.3.1
software (PerkinElmer). The fluorescence specific signal was
shown as the radiant efficiency (emission light [photons/sec/
cm2/str]/excitation light [μW/cm2]). The fluorescence signal
for each individual well was counted by selecting region of
interest (ROI) and quantifying as the total radiant efficiency
([photons/sec]/[μW/cm2]).
In Vivo Labeling of Primary Tumor. Seven weeks old
female BALB/c mice were injected into the mammary fat pad
with 100,000 4T1-Luc cells (Bioware Ultra, PerkinElmer).
After 10 days, mice were intravenously injected with ICG or
HFn−ICG (3.8 mg/Kg). ICG distribution and tumor
accumulation were monitored for 24 h using the in vivo
imaging IVIS Lumina II (PerkinElmer) instrument and the
KARL STORZ NIR/ICG endoscopic system (OPAL1
Technology, equipped with an high-end full HD camera
IMAGE 1 SPIES and a xenon light source D-light P SCB;
KARL STORZ GmbH & Co. KG, Tuttlingen, Germany).
Reported images were acquired 6 and 24 h after injection,
when differences between free and encapsulated ICG were
most evident. Animals have been managed according to
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procedures approved by Italian Ministry of Health (aut.
Number 611/2019-PR).
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